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Abstract
Epidermal melanocytes play an important role in protecting the skin from UV rays, and their functional impairment results in
pigment disorders. Additionally, melanomas are considered to arise from mutations that accumulate in melanocyte stem
cells. The mechanisms underlying melanocyte differentiation and the defining characteristics of melanocyte stem cells in
humans are, however, largely unknown. In the present study, we set out to generate melanocytes from human iPS cells in
vitro, leading to a preliminary investigation of the mechanisms of human melanocyte differentiation. We generated iPS cell
lines from human dermal fibroblasts using the Yamanaka factors (SOX2, OCT3/4, and KLF4, with or without c-MYC). These
iPS cell lines were subsequently used to form embryoid bodies (EBs) and then differentiated into melanocytes via culture
supplementation with Wnt3a, SCF, and ET-3. Seven weeks after inducing differentiation, pigmented cells expressing
melanocyte markers such as MITF, tyrosinase, SILV, and TYRP1, were detected. Melanosomes were identified in these
pigmented cells by electron microscopy, and global gene expression profiling of the pigmented cells showed a high
similarity to that of human primary foreskin-derived melanocytes, suggesting the successful generation of melanocytes
from iPS cells. This in vitro differentiation system should prove useful for understanding human melanocyte biology and
revealing the mechanism of various pigment cell disorders, including melanoma.
Citation: Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, et al. (2011) Generation of Human Melanocytes from Induced Pluripotent Stem Cells. PLoS
ONE 6(1): e16182. doi:10.1371/journal.pone.0016182
Editor: Huck H. Ng, Genome Institute of Singapore, Singapore
Received August 12, 2010; Accepted December 15, 2010; Published January 13, 2011
Copyright:  2011 Ohta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by a grant from MEXT (Ministry of Education, Culture, Sports, Science and Technology), the project for realization of
regenerative medicine and support for the core institutes for iPS cell research from MEXT, and a Grant-in-aid for the Global COE program to Keio University from
MEXT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hidokano@sc.itc.keio.ac.jp (HO); yutakawa@sc.itc.keio.ac.jp (YK)
. These authors contributed equally to this work.
" These authors also contributed equally to this work.
Introduction
Pigmented cells including epidermal melanocytes play an
important physiological role in providing protection from harmful
ultraviolet rays, and are also implicated in various pigmented cell
disorders. Either defects in, or a lack of melanocytes and/or
melanocyte stem cells (MELSCs) can lead to pigment disorders
such as piebaldism, albinism, vitiligo, and hair graying. Vitiligo is a
common disease affecting approximately 0.1 to 2.0% of the world
population, although the pathogenesis has not completely
understood [1]. Autologous cultured melanocytes may be useful
for the treatment of vitiligo [2,3]. In contrast to foreskin
melanocytes, expansion of adult melanocytes is quite difficult.
Thus, development of methods to generate large numbers of
autologous melanocytes is required. Among pigment cell disorders,
melanoma is one of the most aggressive types of human cancers,
and is suspected to arise from MELSCs. The recent progress of
cancer stem cell studies supports the hypothesis that melanoma
stem cells (MMSCs) which are resistant to chemotherapy may
exist, and are thus important therapeutic targets [4,5]. It is
proposed that MMSCs are generated from MELSCs through
accumulation of genetic changes and may have similar phenotypes
to MELSCs [6]. Thus, understanding the biology of human
MELSCs and MMSCs is critically important. In addition, to
permit the investigation of MELSCs and MMSCs, their
purification or generation is required. To date, some candidate
markers for MELSCs (DCT; dopachrome tautomerase, and
PAX3) [7,8] and MMSCs (ABCB5, CD20, CD133, CD271)
[9,10,11,12] have been reported, respectively; however, their
specificity is still controversial. Refining such knowledge will
permit the development of therapeutic treatments against
MMSCs, including immunotherapy.
Melanocytes are specialized cells derived from the neural crest
cells during embryonic development that migrated to hair follicles
and basal layer of the epidermis. A number of studies have shown
that cell factors such as MITF, c-Kit, and Snail/Slug are
important for melanocyte development. Especially, MITF can
regulate the melanocyte lineage in part by regulating several
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[13]. It has been reported that MELSCs locate in the bulge region
of hair follicles in mice [7], however, the localization of MELSCs
in human skin has been unclear due to lack of definitive markers.
It is also difficult to analyze the developmental cell lineages of skin
melanocytes in humans. Thus, it is desirable to develop a new in
vitro system for generating human melanocytes through MELSCs,
which mimics in vivo differentiation processes to better understand
human melanocyte development. Melanocyte generation from
embryonic stem (ES) cells has been previously reported [14,15].
Alternatively, induced pluripotent stem (iPS) cells have specific
advantages compared to ES cells. Besides avoiding ethical issues,
iPS cells can be propagated as autologous cells, meaning that
melanocytes from autologous iPS cells are not likely to be
immunologically rejected if transplanted for the treatment pigment
cell disorders. In addition, melanocytes may be generated from the
iPS cells of patients with genetic pigment cell disorders, leading the
understanding of mechanisms of the diseases, as shown previously
for ALS, Familial dysautonomia, Parkinson’s disease and SMA
[16,17,18,19]. With these considerations, human iPS cells are a
superior starting cell source to generate melanocytes through
neural crest cells in vitro, leading to a better understanding of the
characteristics of MELSCs and MMSCs.
In this study, we have established an in vitro system for
generating human melanocytes from iPS cells, apparently through
a neural crest cell intermediate. This system may contribute to the
understanding of human melanocyte development and various
pigment cell disorders, including melanoma. It may also be useful
for the preparation of large numbers of autologous melanocytes for
treating hypopigmental diseases.
Results
Generation of human iPS cells from human dermal
fibroblasts
We established two human iPS cell lines following the methods
established by Takahashi et al. [20] from dermal fibroblasts using
all four retrovirally expressed Yamanaka factors (4F) (SOX2,
OCT3/4, KLF4, c-MYC) or using three factors (3F) without c-
MYC (Figure 1A and 1B). To examine the expression of
pluripotency markers in both 3F-iPS cells and 4F-iPS cells, we
performed alkaline phosphatase staining (Figure 1C and 1D) and
immunocytochemical analyses on OCT3/4, NANOG, SSEA4,
TRA-1-60, and TRA-1-81 in 3F and 4F-iPS cell colonies
(Figure 1E–I9). In addition, the gene expression profiles of
pluripotent stem cell markers including the endogenous Yamanaka
factors, NANOG and REX1 were analyzed in 3F and 4F-iPS cells
by quantitative PCR analyses and compared to 4F-iPS cells’
parental human dermal fibroblasts and previously characterized
4F-iPS cells, 201B7 [20]. The generated 3F- and 4F-iPS cells
expressed endogenous pluripotency markers similarly to 201B7
iPS cells and ES cells (Figure 1J). Transgene expression was also
examined using quantitative PCR analyses, indicating a similarly
low gene expression level in the both established 3F- and 4F-iPS
cells as compared to 201B7 iPS cells, apart from a higher
expression of retroviral KLF4 in 3F-iPS cells (Supplemental Figure
S1). Evaluation of the methylation status of cytosine guanine
dinucleotides (CpG) in the promoter regions of OCT3/4 was
analyzed by bisulfite sequencing and compared to 4F-iPS parental
dermal fibroblasts. 3F- and 4F-iPS cells were highly unmethylated
in comparison (Figure 1K). Furthermore, the differentiation ability
of both 3F- and 4F-iPS cells was examined in vitro. Floating
embryoid bodies (EBs) were cultivated for 3 weeks from each iPS
cell set, and then spontaneously differentiated onto gelatin coated
dishes for 12 days. Attached cells were immunopositive for three
germ cell layers’ markers (b-III-tubulin, ectoderm; a-smooth
muscle actin, mesoderm; a-fetoprotein, endoderm) (Figure 1L-
1N9). Finally, to confirm the pluripotency of 4F-iPS cells in vivo,w e
transplanted 3F- and 4F-iPS cells into the testis of immunodefi-
cient mice (NOD-SCID) to observe teratoma formation. Tumors
formed eight weeks after injection and contained various tissues
representing all three germ layers (ectoderm, mesoderm, and
endoderm; Figure 1O–1Q9) and various tissues (Supplemental
Figure S2). Collectively, these results confirmed the establishment
of de novo iPS cells from human dermal fibroblasts.
Melanocyte differentiation from human iPS cells
Human 3F- and 4F-iPS cells were cultured as colonies on
mitomycin-C treated feeder cells in iPS medium containing FGF-2
(Figure 2A). To generate melanocytes, EBs were generated from
iPS cells grown in suspension in bacterial culture dishes without
FGF-2 for 3 weeks (Figure 2B) and then plated onto fibronectin-
coated dishes in melanocyte differentiation medium containing
Wnt3a, SCF, ET3, FGF-2, and cAMP inducers (cholera toxin) as
described in Materials and Methods. A week after plating, many
cells migrating out from EBs were observed (Figure 2C), and
culture was continued for an additional 3 weeks, changing the
medium every 2–3 days. After this period, whole attached cells
were dissociated into single cells using TrypLE Select and replated
onto a fibronectin-coated dish in the same melanocyte differen-
tiation medium. Proliferating cells were passaged before reaching
confluence. Pigmented cells usually appeared 3–4 weeks after
single cell dissociation, and most of the cells were highly pigmented
4–6 weeks after single cell dissociation (Figure 2D, 2E). Using our
established system, we can produce approximately 5610
6
melanocytes cells based on the percentage of SILV
+ cells in the
total cell number three months after differentiation from a 10 cm
cell dish containing confluent iPS cell colonies (approximately
2–3610
6 starting iPS cells). We could usually maintain the culture
for a few months. However, proliferative capacity of the cells was
eventually lost, as is typically seen in primary human melanocyte
culture.
Characterization of human melanocytes derived from iPS
cells
To characterize putative melanocytes derived from both 3F-
and 4F-iPS cells, we performed immunocytochemical analyses
using established melanocyte markers. Each set of iPS cell-derived
melanocytes was immune-positive for SLIV, TYRP1, TYR, MITF
and S100 antibodies 8 weeks after differentiation (Figure 3A–J). As
a positive control, we analyzed normal human foreskin-derived
epidermal melanocyte (NHEM) cells isolated from newborn
foreskin using the same antibodies (Figure 3K–O). To further
confirm the generation of melanocytes, melanosome formation in
the pigmented cells was evaluated using transmission electron
microscopy, revealing melanosomes in both 3F- and 4F-iPS-
derived melanocytes (Figure 3P and 3Q) as seen in NHEM
(Figure 3R). In addition, transcripts of MITF-M, which is a MITF
gene-isoform known to be expressed in melanocytes and c-Kit that
is a marker of melanoblasts and melanocytes were expressed in 3F-
iPS cell derived melanocyes (Figure 3S). To compare the efficiency
of melanocyte generation from 3F- and 4F-iPS cells, the
population of SILV-positive cells was compared 7 weeks after cell
differentiation and the almost same differentiation efficiency was
observed between 3F- and 4F-iPS derived cells (Figure 3T).
Finally, scatter plot analyses were performed using DNA
microarray to compare the global gene expression between
NHEM and melanocytes derived from 3F-iPS cells at 8 weeks
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profile was observed between those samples. These data strongly
support that our differentiation conditions are capable of directing
the generation of NHEM-like epidermal melanocytes from iPS
cells (Fig. 3U).
iPS cells differentiate into cells expressing neural crest
and melanocyte stem cell markers
Melanocytes are known to be derived from neural crest cells in
early development and their numbers are believed to be sustained
by melanocyte stem cells in dermal tissues in vivo. To identify the cell
origin of iPS cell derived-melanocytes in this study, we analyzed
expression of the neural crest marker Slug, and one of the putative
melanocyte stem cell markers PAX3, melanoblast and melanocyte
marker MITF, as well as the pluripotency marker NANOG, using
quantitative RT-PCR. The expression of neural crest marker genes
was observed in EB-derived cells cultured on fibronectin-coated
dishesinmelanocytedifferentiation mediumfor7 days and the gene
expression of NANOG was silenced in 3F-iPS MEL (Figure 4A).
We also performed flow cytometric and immunocytochemical
analyses on EB-derived cells cultured in melanocyte differentiation
medium for one week. Flow cytometry showed the presence of
neural crest marker p75 and HNK-1 double-positive cells, which
are derived from 3F-iPS cell EBs (Figure 4B). Immune-positive cells
for the neural crest markers, p75, HNK-1, and AP2a, were
observed in migrating cells from EBs one week after differentiation
(Figure 4C). The immune-positive cells for a neural crest cell
marker, SOX10, [21] and a possible adult melanocyte stem cell
marker, PAX3 [22,23], were also observed in the EBs-derived cells
cultured in melanocyte differentiation medium for a week,
indicatingthat the iPS-derived melanocytesmaybederived through
neural crest cells and melanocyte stem cells as is the case for in vivo
melanocyte development (Figure 4D).
Discussion
In this study, we established an in vitro method of deriving
human melanocytes from iPS cells generated using either four
Figure 2. Generation of melanocytes from iPS cells. EfficientdifferentiationofhumaniPScellsintopigmentedmelanocytesindefinedconditions.
(A) A representative image of a 3F-iPS cell colony grown on a Mitomycin-C-treated STO feeder layer. (B) Embryoid bodies (EBs) formed in suspension
under feeder-freeconditions. (C) After one weekindifferentiationmedium,cells were observed migratingout fromEBsona fibronectin–coatedplate.(D)
Morphology of putative melanocytes differentiated from human EBs 7 weeks after differentiation. Cells display melanocytic morphology and
pigmentation. (E) Pigmented cell pellet of iPS cell-derived melanocytes 9 weeks after differentiation. Scale bar, 100 mm (A, B, C), 40 mm( D ) .
doi:10.1371/journal.pone.0016182.g002
Figure 1. Induction of human 3F- and 4F-iPS cells from adult dermal fibroblasts and characterization of their pluripotency.
(A) Morphology of human dermal fibroblasts. (B) Representative image of an established iPS cell colony cultured on mitomycin C-treated STO feeders.
(C, D) Alkaline phosphatase (AP) staining in a 3F- (C) and 4F- (D) iPS cell colony. (E–I9) Expression of pluripotency markers in established 3F- and 4F-iPS
colonies. 3F-iPS (E–I) and 4F-iPS (E9–I9) colonies express markers common to pluripotent cells including OCT3/4, NANOG, SSEA-4, TRA-1-60, and TRA-1-
81. DAPI (4, 6-diamidino-2-phenylindole) staining indicates the total cell content per field. Scale bars, 20 mm (A), 100 mm (B, C, and D), 50 mm (E–I9).
(J) Expression of pluripotency genes. Endogenous gene expression levels of OCT3/4, SOX2, KLF4, c-MYC, NANOG, and REX1 were determined by
quantitative PCR in parental human dermal fibroblasts (HDF), 3F- and 4F-iPS cells, 201B7 (4F-iPS cells) [20] and ES cells (KhES-1). The graphs show the
average of two independent experiments. Error bar indicates mean6S.E.M. (K) iPS cells are demethylated at the OCT3/4 promoter relative to their
parental fibroblasts. Bisulfite sequencing analysis of the OCT3/4 promoter in parental HDFs, 3F-, and 4F-iPS cells. Each horizontal row of circles
represents an individual sequencing reaction for a given amplification. White circles represent unmethylated CpG dinucleotides; black circles
represent methylated CpG dinucleotides. (L–N9) Images of differentiated cells at day 12. 3F- (L–N) and 4F-iPS (L9–N9) cells were cultured in suspension
to form EBs for three weeks and then transferred to gelatin-coated plates and cultivated for another 12 days. Immunocytochemical analyses showed
positive cells in spontaneously differentiated iPS cell colonies for b-III tubulin (ectoderm, L and L9), a-smooth muscle actin (a-SMA, mesoderm, M and
M9), and a-fetoprotein (AFP, endoderm, N and N9). Scale bar, 50 mm. (O–Q9) Generation of teratoma-like masses in testis by xenograft of 3F- and 4F-
iPS. Paraffin-embedded sections were stained with hematoxylin and eosin. Resulting teratomas display features of ectoderm (O and O9), mesoderm (P
and P9) and endoderm (Q and Q9). Scale bar, 100 mm.
doi:10.1371/journal.pone.0016182.g001
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PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16182Figure 3. Marker expression characteristic of the melanocyte lineage in human iPS cell-derived melanocytes observed 8 weeks
after differentiation. Either 3F- (3F-iPS MEL, A–E) or 4F- (4F-iPS MEL, F–J) iPS cells derived melanocytes were positive for an array of melanocyte
markers: SILV (silver protein), TYRP1 (tyrosinase-related protein-1), TYR (tyrosinase), MITF (microphthalmia-associated transcription factor) , and S100.
Normal human epidermal melanocytes (NHEM) were also stained with the same antibodies (K–O). Transmission electron microscopy images of either
3F (P), 4F (Q)-iPS cells derived melanocytes, or NHEM (R) showed that those melanocytes have many melanosomes in the cytoplasm. Scale bar, 20 mm
(A–O), 0.5 mm (P, Q, and R). (S) Quantitative real-time PCR analysis of MITF-M and c-Kit in 3F-iPS, 3F-iPS MEL, and NHEM. The data are normalized to
GAPDH and represented as fold change relative to RNA levels in 3F-iPS. The graphs show the average of two independent experiments. Error bar
indicates mean6S.E.M. (T) Quantitation of SILV-positive cells induced from 3F and 4F-iPS cells. Percentage of SILV positive cells upon total
Epidermal Melanocytes from iPS Cells
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Yamanaka factors. Of note, deriving melanocytes from 3F-iPS
cells should reduce the risk of tumorigenesis, based on data from a
previous study [24]. Developing an in vitro human melanocyte
differentiation system is important for following the reasons: 1) in
addition to understanding human melanocyte biology, melano-
cytes generated from human iPS cells may be applied to
autologous cell transplantation for patients with various pigment
cell disorders such as vitiligo; 2) using patient-specific iPS cells, this
in vitro system may help to reveal the mechanisms of human
genetic pigment disorders or even melanoma oncogenesis,
particularly through making research on MELSCs and MMSCs
more accessible.
During embryonic development, the precursors of melanocytes
are non-pigmented melanoblasts derived from the neural crest
cells. Developmentally, embryonic melanoblasts differentiate into
either mature melanocytes or MELSCs for maintaining the
melanocytic system in the adult [21]. Especially in mouse,
MELSCs are located in the hair follicle bulge region [7] and
appear to be supported by a specialized niche [25], although
MELSCs may also be located in other regions including dermis, as
shown in humans. In fact, OCT4 positive-human dermal stem
cells generated from foreskins lacking hair follicles have been
reported to be differentiated into melanocytes [26]. Although
candidate MELSC markers, DCT and PAX3, have been reported
in mouse [7,8,22], it is still difficult to identify MELSCs
populations, especially in humans, without more specific markers.
In our in vitro development system, we observed the appearance of
some neural crest cell marker-positive cells one week after EBs
differentiation, supporting the notion that iPS-derived melanocytes
may be sequentially generated from neural crest cells, mimicking in
vivo development. In addition to MELSCs [7], human skins
contain various stem cell populations such as hair follicle
epidermal stem cells [27], hair follicle stem cells [28], bulge
neural crest-derived stem cells [29,30], and skin-derived precursors
(SKPs) [31]. It may also be possible to generate such stem cell
populations by modifying this culture system starting from iPS
cells, eventually leading to better understanding of such human
skin progenitor and/or stem cell populations.
Cancer cells including melanoma are suspected to be derived
from stem/progenitor cells in which genetic alterations have
accumulated [6]. Additionally, cancer stem cells, which have a
high tumor initiating ability and cause relapses due to chemo-
therapy resistance have recently been proposed. Thus, cancer stem
cells appear to be an important target for treatment [32]. It was
suggested that cancer stem cells may have a similar phenotype as
normal tissue stem cells in some cancers. However, the existence
and phenotype of MMSCs is still controversial [33], despite
various possible markers such as CD20, CD133, CD271, or
ABCB5 having been previously suggested [12,34]. Identification of
human MELSCs, or the generation of melanoma cells via
melanoma-causing genetic alterations using this in vitro human
melanocyte differentiation method from iPS, may lead to further
insights into MMSC biology and subsequent development of new
treatments targeting MMSCs.
It is important to establish methods to identify good quality
human iPS cell clones that are free from tumor development. The
safety of the melanocytes generated must still be examined by
engraftment in immunodeficient mice. Additionally, based on the
percentages of SILV-positive cells, our differentiated cell popula-
tions do not appear completely homogeneous. Thus, efforts to
increase the purity of differentiated populations, including the
removal of immature and/or undifferentiated cells that may be
tumorigenic [35], are important to warrant safety prior to clinical
cell therapies. In addition, to reduce the risk of tumorigenicity, use
of L-MYC instead C-MYC may be an optional choice for the
generation of clinical grade iPS cells [36]. In this study, we
generated iPS cells using a retrovirus system, and observed
imperfect transgene silencing in 3F-iPS as shown in supplemental
data; thus, in the future we should develop new methods of
generating clinical grade iPS cells without genomic integration of
retroviral transgenes, in addition to generating homogeneous iPS
clones based on the expression level of the four Yamanaka factors
and NANOG.
The technique described herein is especially important for
pigment cell disorders, as establishment and expansion of adult
melanocytes are both challenging processes. Melanocytes from
autologous iPS cells have an obvious advantage over ES cells, due
to a negligible chance of immunological rejection, above and
beyond surpassing ethical issues. Collectively, it may be important
to find technology to select and/or increase iPS cell clones that can
generate melanocytes with high yield, as each iPS cell clone may
have different differentiation potency. In our culture system, the
generation of neural crest cells was observed during the
differentiation process. Although developmental models suggest
that neural crest cells would also act as the source for melanocytes
in vitro, we were unable to directly demonstrate this linearity in our
differentiation system. We are now optimizing the isolation of
intermediate neural crest cells using cell sorting in an attempt to
increase the purity and quantity of melanocyte culture. Recently
efficient methods to generate neural crest cells from human ES
and iPS cells using SMAD inhibition have been reported [37].
Combining our current procedure with SMAD inhibition may
ultimately increase the yield of melanocytes through the efficient
induction of a transient neural crest cell population. In the future,
we predict we will be able to achieve much higher efficiencies of
melanocyte derivation by enrichment of either neural crest cells or
MELSCs through chemical and/or physical means.
In the present study, we used Wnt3, SCF, ET3, and cAMP
inducers (cholera toxin) in our melanocyte differentiation medium.
MITF regulates melanocyte lineage by activating pigment-
producing genes such as DCT and tyrosinase, and contributes to
cell survival by up-regulating anti-apoptotic genes Bcl-2 and
BclXL [38]. The MITF promoter is regulated by the transcription
factors, PAX3, SOX10, LEF1, and CREB, all of which are
downstream signaling molecules of Wnt, ET3, SCF, and cAMP
[39]. Therefore, we believe our differentiation conditions bias
melanocyte differentiation through a combinatorial activation of
MITF. We are currently trying to improve the compositions of our
differentiation medium to further increase the yield of melanocytes
and reduce the number of components as more simple
compositions would be desirable to generate GMP (good
manufacturing practice) grade melanocytes for use in future
clinical applications.
In summary, we have established in vitro differentiation system
for human melanocytes from 3F- and 4F-iPS cells. Recently, many
differentiation of EBs cells 7 weeks after differentiation under melanocyte differentiation medium. Error bar indicates mean6S.E.M (3F-iPS, n=3; 4F-
iPS, n=2). (U) The global gene-expression patterns were compared between human 3F-iPS cells and 3F-iPS derived-MEL (3F-iPS MEL), and between
NHEM and 3F-iPS MEL. The lines indicate the linear equivalent and 5-fold differences on either side in gene expression levels between the two
samples.
doi:10.1371/journal.pone.0016182.g003
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16182Figure 4. 3F- and 4F-iPS cells can be differentiated into NCSC and MELSCs. (A) Gene expression analysis of a neural crest stem cell marker
(Slug), a melanocyte stem cell marker (PAX3), a melanocytic marker (MITF), pluripotency marker (NANOG) in 3F-iPS cells, differentiated cells derived
from EBs on fibronectin-coated plates in melanocyte differentiation medium at 7 days after differentiation (EB-DIFF), and 3F-iPS derived melanocytes
(3F-iPS MEL). Transcript levels were normalized to GAPDH. The graphs show the average of two independent experiments. Error bar indicates
mean6S.E.M. (B) Representative flow cytometry results for HNK-1 and p75 staining in 3F-iPS EB-derived cells cultured in melanocyte differentiation
medium for one week. Dead cells were excluded using PI staining. (C) Immunocytochemistry revealing cells positive for NCSC markers (p75, HNK-1,
and AP2a) in both 3F- and 4F-iPS cells derived EB-differentiated cells 7 days after differentiation. Scale bar, 50 mm. (D) Images show cells positive for
neural crest cell marker SOX10, as well as possible melanocyte stem cell marker, PAX3 in both 3F- and 4F-iPS cell-derived EB-differentiated cells 7 days
after differentiation. Scale bar, 50 mm and 10 mm (insert images).
doi:10.1371/journal.pone.0016182.g004
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diseases such as ALS, Familial dysautonomia, Parkinson’s disease,
and SMA [40]. If differentiated cells from patient-specific iPS cells
can faithfully recapitulate the disease phenotype, iPS cell
technology will contribute significantly to revealing disease
mechanisms and developing drug screening systems for disease.
Building on this paradigm, further analysis of the mechanism of
melanocyte development using directed differentiation will
contribute to not only human melanocyte biology, but also an
understanding of various pigment cell disorders leading to the
development of new therapeutic strategies.
Materials and Methods
Generation of human induced pluripotent stem (iPS) cells
and ES cell culture
HDFs (human dermal fibroblasts) from facial dermis of a 36-
year-old Caucasian female (Cell Applications Inc, San Diego, CA)
were used for the establishment of 4F-iPS cells (OCT3/4, SOX2,
KLF4, MYC). 3F-iPS cells (OCT3/4, SOX2, KLF) were
generated from primary skin fibroblasts derived from a healthy
16-year-old female volunteer by skin punch biopsy with written
informed consent (Keio University School of Medicine). All
fibroblasts were maintained in DMEM containing 10% FBS. The
induction of human iPS cells was performed as previously
described by Takahashi et al. [20]. Briefly, fibroblasts lentivirally
expressing the mouse receptor for retroviruses (Slc7a1) were
seeded at 3610
5 cells per 60 mm dish, and infected the next day
with retroviruses delivering all four reprogramming factors or
three factors without c-MYC. Seven days after transduction, cells
were harvested by trypsinization and replated at 5610
425610
5
cells per 100 mm dish on a mitomycin C-treated STO feeder layer
(DS Pharma, Osaka, Japan). The next day, the medium was
replaced with human iPS medium containing FGF-2 (4 ng/ml,
Wako, Osaka, Japan). The medium was changed every other day
until colonies were picked. 3F- and 4F-iPS cells, and 201B7 iPS
cells [20] were established and characterized following method-
ology described in the previous study. ES cells (KhES-1) [41] were
cultured on the feeder cells in iPS culture medium. Established iPS
cells are available upon request to Hideyuki Okano (Keio
University).
Spontaneous in vitro differentiation
Embryoid bodies (EBs) were formed from floating culture in EB
medium consisting of DMEM/Ham’s F12 containing 20%
Knockout Serum Replacement (Invitrogen, Carlsbad, CA),
2 mM L-glutamine, 1610
24 M nonessential amino acids,
1610
24 M 2-mercaptoethanol, and 0.5% penicillin and strepto-
mycin in a bacteria dish for 3 weeks. EBs were then transferred to
a gelatin-coated dish in the same iPS medium as described above.
Melanocyte induction from iPS cells
To induce melanocytic differentiation, EBs were derived as
described above, however, after three weeks, EBs were plated on a
fibronectin-coated dish in DMEM and MCDB 201 based
differentiation medium containing 50 ng/ml Wnt3a (R&D
Systems, Minneapolis, MN), 50 ng/ml stem cell factor (SCF,
R&D Systems), 100 mM Endothelin-3 (ET-3, American Peptide
Company, Sunnyvale, CA), 20 pM cholera toxin (Toyobo, Osaka,
Japan), 50 nM TPA (12-tetra decanoyl-phorbol 13-acetate, Sigma-
Aldrich, St Louis, MO), 4 ng/ml FGF-2 (WAKO), 100 mML -
ascorbic acid (Sigma), 0.05 mM dexamethasone (Sigma), 1 mg/ml
linoleic acid-bovine serum albumin (Sigma), and 1X insulin-
transferrin-selenium (Sigma) following the method described by
Fang et al. [14]. Before attaining confluence, cells were dissociated
using TrypLE Select (Invitrogen) and replated onto a fibronectin
(BD Biosciences, San Jose, CA)-coated dish in differentiation
medium until the appearance of pigmented cells and continued to
be cultured for few months.
Human melanocyte culture cells
Cultured normal human foreskin-derived epidermal melanocyte
(NHEM) cells were obtained from Kurabo (Osaka, Japan).
Melanocytes were maintained in melanocyte complete 254 culture
medium (Kurabo) supplemented with 0.5% fetal bovine serum,
5 mg/ml insulin, 0.5 mM hydrocortisone, 5 mg/ml transferring,
3 mg/ml heparin, 3 ng/ml human FGF-2, 10 ng/ml phorbol-12-
myristate-13-acetate, and 0.2% bovine pituitary extract.
Teratoma formation
For iPS injection into the testis of 8-week-old NOD/SCID mice
(OYC International, Tokyo, Japan), a 1 cm longitudinal incision
in the abdominal wall was made, and the testis was exteriorized.
One million iPS cells were inoculated into the testis parenchyma
with a Hamilton pipette, and the wound was sutured. Eight weeks
after injection, tumors were dissected and fixed with PBS
containing 4% paraformaldehyde (PFA). Paraffin-embedded
tissues were sectioned and stained with hematoxylin and eosin.
RT-PCR
Total RNA was purified with Trizol reagent (Invitrogen) and
PureLink RNA Mini Kit (Invitrogen) after DNAase I treatment to
remove genomic DNA. cDNA synthesis was performed using
High Capacity RNA-to-cDNA Master Mix (Applied Biosystems,
Forster City, CA) according to the manufacturer’s instructions.
The primers were designed as follows: c-Kit forward primer, 59-
GTTCTGCTCCTACTGCTTCGC-39; reverse primer, 59-TAA-
CAGCCTAATCTCGTCGCC-39, MITF forward primer, 59-
TGCCCAGGCATGAACACAC-39; reverse primer, 59-TG-
GGAAAAATACACGCTGTGAG-39; MITF-M forward primer,
59-ACCTTCTCTTTGCCAGTCCATCT-39; reverse primer,59-
GGACATGCAAGCTCAGGACT-3, PAX3 forward primer, 59-
AGCCGCATCCTGAGAAGTAA-39; reverse primer, 59-CT-
TCATCTGATTGGGGTGCT-39, Slug forward primer, 59-CA-
TACAGCCCCATCACTGTG-39; reverse primer, 59-CTTG-
GAGGAGGTGTCAGATG-39; GAPDH, forward primer, 59-
TGAACGGGAAGCTCACTGGG-39; reverse primer,TCCAC-
CACCCTGTTGCTGTA-39.
For the detection of gene expression of OCT3/4, SOC2, KLF4,
c-MYC, NANOG, and REX1, primer sets published in Takahashi
et al. [20] were used. The detection of transgene expression, we
used sequence specific primer sets for these genes. Quantitative
PCR was performed using Thunderbird syber qPCR Mix
(Toyobo). Transcript levels were determined using the ABI
PRISM Sequence detection System 7900HT (Applied BioSys-
tems). Gene expression was normalized to GAPDH as an internal
standard.
Bisulfite Sequencing
Genomic DNA was purified from each set of cells using a
Wizard SV Genomic DNA Purification Kit (Promega, Tokyo,
Japan). Bisulfite conversion was performed with 500 ng of
genomic DNA using the reagents provided in Qiagen’s EpiTect
Bisulfate kit (Qiagen, Tokyo, Japan). The promoter region of
human OCT3/4 (22344 to 22126) was amplified using primers
following the study by Freberg et al. [42]; forward primer, 59-
ATTTGTTTTTTGGGTAGTTAAAGGT-39; reverse primer,
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e1618259-CCAACTATCTTCATCTTAATAACATCC-39. The PCR
products were subcloned into pGEM-T Easy (Promega) and
sequenced. Twelve clones of each sample were verified by
sequencing with the T7 universal primer.
DNA Microarray
Approximately 10
6 cells were used for total RNA extraction
using the PureLink RNA Mini Kit (Invitrogen), according to the
manufacturer’s instructions. RNA quality was verified with the
Bioanalyser System (Agilent Technologies, Paolo Alto, CA), using
RNA Nano Chips. 1 mg of RNA was processed for hybridization
on the Whole Human Genome Microarray4644k (Agilent).
Processing was done according to the recommendations of the
manufacturer. All genomic and transcriptomic analysis was carried
using GeneSpring software 7.3.1. (Agilent). Signal intensities less
than 0.01 were set to 0.01, then each chip was normalized to the
50th percentile of the measurements taken from that chip.
Flow cytometry
Cells were analyzed using an EPICS XL instrument (Beckman-
Coulter). Prior to flow cytometry, cells were dissociated with
Accumax (Innovative Cell Technologies, San Diego, CA) for
15 min at room temperature and then filtrated with 40 mm cell
strainers. CD57 (HNK-1) FITC-conjugated antibody (Beckman-
Coulter), CD271 (p75) PE- conjugated antibody (Biolegend, San
Diego, CA), Mouse IgG-PE isotype antibody, and Mouse IgM-
FITC isotype antibody were used for immunolabeling. Propidium
Iodide (PI) staining excluded dead cells.
Immunocytochemical analysis and alkaline phosphatase
staining
For immunocytochemistry, cells were fixed with phosphate
buffered saline (PBS) containing 4% PFA for 20 min at room
temperature. Then, cells were subjected to immunofluorescence
staining using the following primary antibodies: a-fetoprotein
(AFP) (1:500, DAKO, Kyoto, Japan), a-smooth muscle actin
(SMA) (1:100, Sigma), AP2a (1:50, Cell Signaling Technology,
Beverly, MA), b-III-tubulin (1:1000, Sigma), microphthalmia-
associated transcription factor (MITF) (1:50, Thermo Scientific,
Rockford, IL), HNK-1 (1:200, Millipore, Billerica, MA), NANOG
(1:1000, Reprocell, Tokyo, Japan), OCT3/4 (1:200, BD Biosci-
ence, San Diego, CA), p75 (1:100, Advanced Targeting Systems),
PAX3 (1:100, R&D Systems), S100 (1:500, DAKO), silver protein
(SILV) (1:50, DAKO), SOX10 (1:100, Abcam), SSEA-4 (1:200,
Millipore), TRA-1-60 (1:200, Millipore), TRA-1-81 (1:200,
Millipore), tyrosinase (TYR) (1:100, Santa Cruz Biothechnology,
Inc., Santa Cruz, CA), tyrosinase-related protein-1 (TYRP1) (1:20,
COVANCE, Princeton, NJ). After PBS washes, antibody binding
was visualized using either Alexa Fluor 488 or 546-conjugated
secondary antibodies (Invitrogen), and the nuclei were stained with
DAPI (49,6-diamino-2-phenylindole). Images were obtained using
a Zeiss LSM-510 confocal microscope (Zeiss, Tokyo, Japan).
Alkaline phosphatase staining was performed using the Leukocyte
Alkaline Phosphatase kit (Sigma).
Electron microscopy
Cells were fixed with 2.5% glutaraldehyde and 4% PFA in
0.1 M cacodylate buffer (pH 7.4) and post-fixed with 1% OsO4.
Images were obtained using an electron microscope (Japanese
Electronic Optical Laboratories, JEOL-1230).
Supporting Information
Figure S1 Quantitative PCR for expression of retroviral
transgenes in human iPS cells.
(TIF)
Figure S2 Analysis of differentiated cells in teratoma.
(TIF)
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